



Generic Name: Cetuximab

Pronunciation: seh TUX ih mab

TradeName: Erbitux

Overview:

- Cetuximab is a recombinant monoclonal antibody (antibody produced from a single clone of cell)
- It binds to Epidermal Growth Factor Receptors (EGFR) of cancer cells and inhibits their activation. This stops the cancer cells from dividing.
- It is a sterile, clear, colorless liquid with pH between 7.0 to 7.4.
- It is supplied as a 50 ml vial at a concentration of 2 mg/mL in phosphate buffered saline.

Why it is prescribed (Indications):

- · Cetuximab, along with radiation therapy, is used for patients with locally or regionally advanced squamous cell carcinoma of the head and neck.
- It is given to patients with recurrent or metastatic squamous cell carcinoma of the head and neck, for whom platinum-based therapy had failed.
- In combination with Irinitecan, Cetuximab is used for treatment of patients with colorectal carcinoma.
- · It is prescribed, as a single agent, to patients with metastatic colorectal carcinoma with intolerance to Irinotecan-based therapy.

When it is not to be taken (Contraindications):

• There are no known contraindications for Cetuximab.

How it should be taken:

- It is given intravenously as a drip. It should not be administered as an IV push or bolus but as an IV infusion pump or infusion syringe
- Initially it is given slowly, for two hours.
- The recommended dose of the first infusion or loading dose of Cetuximab is 400 mg/m2, either in combination with Irinothecan or as a single agent
- · All the other infusions given weekly, known as maintenance dose, with a concentration of 250 mg/m2, is given for an hour.
- It should be given with the use of a low protein binding 0.22-micrometer inline filter.

Special Instruction:

• No drug interaction has been reported for Cetuximab.

Side Effects:

The following are the list of side effects due to Cetuximab.

- Feeling of weakness
- Fever
- Headache
- Nausea
- Constipation Anorexia
- Breathlessness
- Vomiting
- Dehydration
- Pharyngitis
- Acne-like rashes

Other Precautions:

- · While using Cetuximab, patients are advised to use sun screen, hats and limit exposure to the sun, as it may exacerbate any skin reaction that may
- · Cetuximab, in combination with radiation therapy, should be used with caution in patients with known history of coronary artery disease, arrhythmias and congestive heart failure.

Storage Conditions:

- The vials should be stored at 2°C to 8°C
- They should never be frozen.
- Prepared Cetuximab infusions are chemically and physically stable for up to 12 hours at 2°C to 8°C and up to 8 hours at 20°C to 25°C.

• Unused portions of the vials must be discarded.

Note: This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.



Taj Group of Companies INDIA

Taj Pharmaceuticals Ltd.

Phone: General EPA BX: 91 - (0)22 - 26374592/92 91, (0)22 - 26374592/93 91 - (0)22 - 30601000,

Fax: 91-(0)22-26341274

Revised November 2010